A 5-year-old girl with acute lymphoblastic leukemia has invasive candidiasis. Her initial therapy with an echinocandin results in a good clinical response. The team wants to transition to an oral agent as she is now stable and not critically ill. Which of the following is an acceptable step-down therapy?